Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg maintains 'buy' rating on Next

(Sharecast News) - Analysts at Berenberg reiterated its 'buy' rating on retailer Next in view of "some interesting medium-term growth angles". Berenberg pointed to Next's online overseas business, its ongoing development of Next products and wholly-owned brands, the new "Seasons" premium section of its website, and profit growth from a long list of equity stakes in other retailers.

"We favour Next's majority online exposure, as we believe that the current outperformance of online clothing sales versus store sales in the market result from a return of a structural trend following a post-pandemic online correction," said the German bank.

It also noted that Next has about 20% of sales in its home division, a product segment that seems to be "edging back to growth in the UK" after an extended period of decline following the Covid-19 pandemic.

"We value Next using a 15-year DCF featuring a 9% WACC, 2% terminal growth and a 19% terminal adjusted EBIT margin. We apply a 15% premium to the DCF valuation to reach a price target that reflects the appeal of long-trusted management at Next," said Berenberg, which has a 12,600.0p target price on the stock.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.